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FACTORS AFFECTING HEME TRANSFER FROM “GAPDH”, A
POSSIBLE HEME CARRIER PROTEIN

RAJESH VEMPATI
ABSTRACT
The aim of my research is to understand the mechanism of heme transfer by
carrier proteins into heme proteins. The mechanism of heme insertion into proteins
is poorly understood. Previous experiments reported from our lab identified
GAPDH as a possible heme carrier protein involved in heme transfer (Ritu
Chakravarti et al PNAS). This work focuses on 2 aspects of heme transfer. a.) Rate
of transfer of heme from GAPDH to apomyoglobin. We examined the rate of
transfer of native proto-heme and the analogue meso-heme. The results showed
that the rate of heme transfer was twice as fast for meso-heme compared to the
native proto-heme, for both human and rabbit GAPDH’s. This suggests that
structural factors may be important for heme transfer from GAPDH to apomyoglobin.
b.) Nitrosylation of GAPDH and its effect on rate of heme transfer. We went on to
examine different factors that could affect the extent of nitrosylation. The factors
which we examined were dose of nitrosylation donor, pH, and stability of
nitrosylated protein with temperature and presence of oxygen. 1.) Increasing the
dose of nitrosylation donor increased the extent of nitrosylation in the case of
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human GAPDH, in contrary with rabbit GAPDH nitrosylation which is not
dependent on dose 2.) Nitrosylated protein is more stable at 4oC than at room
temperature. 3.) The extent of nitrosylation increased as the pH increases in case
of rabbit GAPDH, however human GAPDH nitrosylation was favored at slightly
acidic and alkaline compared to neutral pH. Reducing agents like DTT, tertiary
amines like HEPES buffer and oxygen were found to have no effect on extent of
nitrosylation. Previous cell biology work from our lab suggests that nitrosylation
of Cys152 in vivo diminishes heme binding property of GAPDH. Cysteine
residues that underwent nitrosylation were identified by mass spectrometry. The
results from mass spectrometry suggest that the levels of nitrosylation on each
individual cysteine are species-specific. In fact, rabbit and human GAPDH showed
different levels of nitrosylation. In parallel site-directed mutagenesis was used to
determine which one of the nitrosylated cysteine mutants had an effect on the rate
of heme transfer. The results suggest that nitrosylation of wild type and different
point mutants of GAPDH doesn’t affect the rate of heme transfer, indicating that
there is no substantial effect of S-nitrosylation on rate of heme transfer (Mild
increase in rate of heme delivery for 2 cysteine mutants, C152/156S and C156S
after nitrosylation).
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CHAPTER I
INTRODUCTION

1.1 Heme proteins:
Heme proteins are important proteins which play vital roles in physiology such as
free radical elimination, signal transduction, oxygen transport, and electron
transfer. Heme exists as a prosthetic group in several heme proteins, heme is an
essential regulator of gene expression (1). The most common heme type is Feprotoporphyrin which is heme B and others include A, C and O which are less
common (2, 3). The last step in heme biosynthesis is the insertion of an iron atom
into protoporphyrin which is catalyzed by ferrochelatase in the mitochondria (4,
5). Free heme is toxic to cells since it can cause damage to DNA, proteins and
lipids by generating reactive oxygen species (ROS) therefore, cells keep tight
control on free heme (6). Until now there is no confirmation how heme travels
from mitochondria to heme proteins like myoglobin, hemoglobin, NOS and
guanylate cyclase which are present in cytosol. A protein carrier involved in
transporting heme from mitochondria to heme proteins has been proposed but yet
1

to be confirmed, until now there is no established pathway how heme gets
incorporated into heme proteins.

1.2 Mechanism of heme delivery:
Previous studies in our lab about heme insertion into heme proteins such as
myoglobin, hemoglobin and NOS suggest the role of carrier proteins in heme
insertion (7). Previous research in our lab suggested that two proteins are
important for heme insertion into apo-protein targets: Hsp90 and GAPDH. Heat
shock protein (hsp90) plays a role in enabling heme insertion into cytokine
inducible mouse NOS. Studies showed hsp90 was associated more with heme free
iNOS, as compared to heme containing iNOS. Also, kinetic data suggested that
cellular heme insertion coincided with hsp90 dissociation. The data also suggests
that ATP deficient hsp90 blocked cellular heme insertion into heme free iNOS,
Together, these observations suggest a potential role of hsp90 in cellular heme
insertion into iNOS (8).
There are notable interactions between iNOS and GAPDH as determined by
surface plasmon resonance, which suggests that GAPDH is a possible heme carrier
protein to iNOS. It was also proposed that nitrosylation at Cys152 on GAPDH
diminished the heme binding property of GAPDH (9).
GAPDH is one of the key enzymes in glycolysis. GAPDH catalyzes the
conversion of glyceraldehyde-3-phosphate to high energy phosphate 1, 3bisphosphoglycerate which is reversible and also first step in glycolysis (10).
2

GAPDH is involved in apoptosis, transcription activation, and may be heme
carrier protein (11-14). GAPDH exists as a tetramer of 4 identical polypeptides
each of 37kDa approximately. The human protein has 335-aminoacid, whereas in
rabbit it is 333-aminoacid per monomer. Four subunits, which are designated as O,
P, Q and R form the homotetrameric human liver GAPDH, which has 3 nonequivalent interfaces P, Q, and R. Fo-Fc difference map shows positive density
around the active-site cysteine 152 of all 4 subunits. Rabbit skeletal muscle
GAPDH is also very similar to human GAPDH as their sequence similarity was
very high. The alignment shows 99% similarity between human and rabbit
GAPDH which is represented in Fig.1.1
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Accession numbers for the protein sequences:
Human GAPDH: P04406
Rabbit GAPDH: P46406
Query

2

Sbjct

4

Query

62

Sbjct

64

Query

122

Sbjct

124

Query

182

Sbjct

184

Query

242

Sbjct

244

Query

302

Sbjct

304

VKVGVNGFGRIGRLVTRAAFNSGKVDVVAINDPFIDLHYMVYMFQYDSTHGKFHGTVKAE
VKVGVNGFGRIGRLVTRAAFNSGKVD+VAINDPFIDL+YMVYMFQYDSTHGKFHGTVKAE
VKVGVNGFGRIGRLVTRAAFNSGKVDIVAINDPFIDLNYMVYMFQYDSTHGKFHGTVKAE

61

NGKLVINGKAITIFQERDPANIKWGDAGAEYVVESTGVFTTMEKAGAHLKGGAKRVIISA
NGKLVING ITIFQERDP+ IKWGDAGAEYVVESTGVFTTMEKAGAHL+GGAKRVIISA
NGKLVINGNPITIFQERDPSKIKWGDAGAEYVVESTGVFTTMEKAGAHLQGGAKRVIISA

121

PSADAPMFVMGVNHEKYDNSLKIVSNASCTTNCLAPLAKVIHDHFGIVEGLMTTVHAITA
PSADAPMFVMGVNHEKYDNSLKI+SNASCTTNCLAPLAKVIHD+FGIVEGLMTTVHAITA
PSADAPMFVMGVNHEKYDNSLKIISNASCTTNCLAPLAKVIHDNFGIVEGLMTTVHAITA

181

TQKTVDGPSGKLWRDGRGAAQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPTPNVSVV
TQKTVDGPSGKLWRDGRGA QNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPT NVSVV
TQKTVDGPSGKLWRDGRGALQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPTANVSVV

241

DLTCRLEKAAKYDDIKKVVKQASEGPLKGILGYTEDQVVSCDFNSATHSSTFDAGAGIAL
DLTCRLEK AKYDDIKKVVKQASEGPLKGILGYTE QVVS DFNS THSSTFDAGAGIAL
DLTCRLEKPAKYDDIKKVVKQASEGPLKGILGYTEHQVVSSDFNSDTHSSTFDAGAGIAL

301

NDHFVKLISWYDNEFGYSNRVVDLMVHMASKE
NDHFVKLISWYDNEFGYSNRVVDLM HMASKE
NDHFVKLISWYDNEFGYSNRVVDLMAHMASKE

63

123

183

243

303

333
335

Query= rabbit GAPDH
Sbjct= human GAPDH

Fig.1.1. The above figure represents the alignment of human and rabbit GAPDH and the
highlighted residues represent cysteines. The alignment was carried out using the blast tool at
http://blast.ncbi.nlm.nih.gov/Blast.cgi.

However there are certain differences as in case of human GAPDH each subunit
is bound to NAD+ and in the case of rabbit skeletal GAPDH only 2 subunits P and
R binds to NAD+. The other difference is in their side-chain conformation of
Arg234. Two residues, cysteine152 and histidine179 play major roles in catalysis.
Cysteine152 provides a sulfhydryl group for nucleophilic effect on G3P and
histidine179 functions as a base catalyst to facilitate hydride transfer (15, 16). Our
lab has found that the catalytic properties of GAPDH are not affected by heme
binding (Unpublished data).

4

Fig.1.2. Crystal structure of human GAPDH, tetramer protein having 4 identical monomers. Each
monomer has 3 cysteines which are shown above at 152, 156 and 247. Cysteine 152 is
responsible for GAPDH activity.
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Rabbit muscle GAPDH crystal structure

c154

Absor
bancec282
of

c244

Fig.1.3. Crystal structure of rabbit muscle GAPDH, Tetramer having four identical monomers
and having close similarity to human GAPDH. Four cysteines are present at 150, 154, 244 and
282. Here cysteine 150 is not shown.

This project deals with rate of heme transfer from GAPDH to apomyoglobin. We
set up an assay to determine the rate of heme transfer from GAPDH heme
complex to Apo myoglobin. We considered different factors, which may have an
effect on the rate of heme transfer from GAPDH-heme complex. The mutant Apo
myoglobin glycerol stock was obtained from Dr. John S. Olson (Rice University,
Texas, USA).
Myoglobin is a monomeric heme protein which is present mainly in muscle tissues
because of its ability to bind oxygen and store it. It is a single chain globular
protein with 154 aminoacids containing heme prosthetic group in its center. The
molecular weight of our mutant is 17.4kDa. It is made of 8 alpha helices joined by
6

short loops, and is water soluble. Each myoglobin has 1 heme prosthetic group
inserted into a hydrophobic cleft in protein. The hydrophobic interactions between
hydrophobic aminoacid group present in the interior side of the cleft and
tetrapyrrole ring stabilize the heme binding to protein (17, 18). Heme binding to
the protein is also stabilized by an axial nitrogen atom provided by histidine 93 at
2.09 angstroms from iron-heme; the iron is also chelated by histidine 64. Our lab
use a mutant form of apo-myoglobin that has an increased affinity for heme
(molecular weight =17.4 K Da). In the mutant apomyoglobin, His 64 is replaced
with Tyr to increase its affinity for heme. Val68 is replaced with phenylalanine
which makes it stable (19, 20).

Crystal Structure of Sperm whale myoglobin

Fig.1.4. Crystal structure of sperm whale myoglobin, Histidine 64 has been replaced by tyrosine
to increase the affinity towards the heme. The heme is represented in yellow. All crystallographic
images were generated with program pymol education edition.

7

The two types of heme for which we studied the rate of heme transfer are protoheme which is native and the meso-heme, which differs on the side chains (R1) as
shown below (21) in Fig.1.5.

Fig.1.5. Structure of Fe-proto and mesoporphyrin IX .

Human GAPDH has a total of 3 cysteines at positions 152, 156 and 247, rabbit
GAPDH has total of 4 cysteines at 150, 154, 245 and 282 respectively. Previous
work from our lab suggests that heme insertion is regulated by NO via specific
nitrosylation of GAPDH in vivo. This project explores an in vitro model to
identify which cysteine is involved in nitrosylation. In addition, we investigate

8

whether a correlation exists between the nitrosylation of specific cysteine and the
rate of heme transfer to apomyoglobin. We determined the extent of nitrosylation
of each specific cysteine on GAPDH by mass spectrometry.

1.3 Nitrosylation:
Nitrosylation of proteins is becoming an important physiological process involved
in major role in host defense, neurotransmission and DNA repair. The transfer of
NO group (nitric oxide) from NO donor to free SH group which are present on
proteins leading in formation of nitrosothiols (RSNO) is known as nitrosylation of
proteins (22). Thiol groups play an important role in quaternary structure and cofactor binding. Free SH group is a good biological nucleophile and is good targets
for electrophiles and also for redox agents which includes nitrosylating and
oxidizing species generated from NO. S-nitrosylation influences protein function
such as enzyme inhibition by blocking active site which is Cys 152. The cysteines
are the main targets for nitrosylation. In general RSNO bond is unstable and hence
it is difficult to quantify (23).
The physiological RSNO’s includes S-nitrosoglutathione (GSNO) and S-nitrosoL-cysteine which have been detected and quantified in vivo (24). Protein Snitrosylation has inhibitory effects on blood clot formation and it is demonstrated
that factor XIII is target for S-nitrosylation on a highly reactive cysteine residue
which has inhibitory effect on blood coagulation and so RSNO’s plays a major
role in hematology (25). S-nitrosylation of GAPDH prevents cytotoxicity by
9

binding with the novel protein GOSPEL (26). Nitrosylation is specific which
means that every free SH group is not nitrosylated and if nitrosylated, nitrosylation
may not be to same extent (27). In our target protein human GAPDH we have 3
cysteines in total at positions 152, 156, and 247 in the primary structure. As per
the results of mass spectrometry we observed that extent of S-nitrosylation varies
on each cysteine. S-nitrosylation inactivates GAPDH, and is reversible as Snitrosylated GAPDH is unstable as SNO bond is liable (28).

Biotin switch technique:
S-nitrosylation of proteins is continuously emerging as physiologically important
modification by which many cell functions are monitored. It is important to
determine which free SH group undergoes nitrosylation and also to determine the
extent of nitrosylation on each individual free SH group. The principle in biotin
switch includes blocking of free SH groups by using thiol blocking agents like
MMTS (methyl methane thiosulfonate) or NEM (N-ethylmaleimide) after
nitrosylation so that only Nitrosylated cysteines are available for biotin in next
step. The next step is reducing the S-Nitrosylated thiol with ascorbate and finally
the reduced form is labeled with Biotin-HPDP. The amount of nitrosylation which
is in terms of biotinylation can be determined by either immunoblotting or by
using mass spectrometry (29, 30).
Modified biotin switch method: This is a slight modification of biotin switch
technique. This has high sensitivity in quantitative estimation of nitrosylation on
10

each individual free thiol group in a protein. Here we replace normal thiol blocker
MMTS with NEM and iodoacetamide for alkylating nitrosylated cysteines instead
of biotin-HPDP.

11

CHAPTER II
EXPERIMENTAL METHODS
2.1 Preparation of heme solution:
The heme solution was prepared by dissolving 10 mg hemin ( MP biomedical pdt
# 02198820) in 4.5 ml water, add little 1 M NaOH (Fisher Scientific# s318-1 CAS
1310-73-2), until visually dissolved. Spectra were collected from 700-300nm
using a Schimadzu UV-VIS spectrophotometer, NaOH was added until
consecutive peaks at 385 nm remain unchanged. Then filter the heme solution
through 0.22 micron filter and collect the filtrate. The concentration of heme was
measured by the heme-chromogen assay.
The heme-chromogen assay was performed using Schimadzu UV-VIS
spectrophotometer. The heme-chromogen reagent was prepared by mixing 400 μl
pyridine, 400 μl water and, 1M 200 μl NaOH. 5 μl heme solution (dilution
depends on concentration of heme solution) was added to 495 μl heme chromagen
reagent, mix with dithionite and incubate for 2-5 minutes. The baseline was taken
with heme chromagen reagent in the cuvette. Spectra were collected from 700-400

12

nm. The peak height at 556 nm was measured, using extinction coefficient of
34600/ M CM (31).

2.2 Preparation of GAPDH-heme complex:
2mg GAPDH from rabbit muscle (sigma PDT# G2267) was dissolved in Hepes
(Fisher Scientific# BP 310-500 CAS 7365-45-9) 50mm/100mm NaCl (NPI CAS#
7647-14-5 >99% pure)/pH 7.4, to achieve a final concentration of 200 μM. Then
the protein solution was incubated with 300 μm heme for 30-45 min at room
temperature. Disposable PD-10 desalting columns (GE health care PDT Code# 17085-01), which were pre packed with sephadex G-25 medium. These were used to
remove unbound small molecules from large molecules like proteins. These PD-10
columns were washed with 5-7 column washes water and equilibrated with 50mm
HEPES/ 100mm NaCl/ pH 7.4. The GAPDH-Heme complex was then passed
through these PD-10 columns. This Pd-10 gel filtration step removes free heme
from protein-heme complex. The fractions each of 500 μl were collected in 1.5 ml
centrifugal tubes and protein concentration of fractions was determined, fraction
containing GAPDH-heme complex was used for further analysis.

2.3 Estimation of Protein concentration:
The concentration of protein was determined by taking spectral scan from 700-250
nm and by measuring peak height at 280 nm using UV-VIS spectrophotometer.

13

The extinction coefficient used for GAPDH was 30000/ M CM. The extinction
coefficient used for apomyoglobin was 15200/M CM.

2.4 Koff or transfer of heme from GAPDH from GAPDH-heme complex to
apomyoglobin:
We established an in vitro system to study the transfer of heme from GAPDHheme complex to apomyoglobin. Multiskan spectrophotometer was used to
measure transfer rates that can read 96wells at same time, this is used to conserve
time and material. The principle involved here, is to monitor the spectral changes
that occur upon heme transfer from GAPDH-heme complex to apomyoglobin.
Spectral changes recorded for 90 minutes with 30 second interval, heme transfer
from GAPDH-heme complex to apomyoglobin is irreversible. 20 μM GAPDH of
200 μL was taken into each well and surrounding wells were filled with water to
prevent evaporation, 40 μM apomyoglobin was added into 3 sample wells, no Apo
myoglobin into control wells. Spectral changes at 398 nm and 700 nm was
recorded for Fe-mesoporphyrin IX and 411 nm and 700 nm for Fe-protoporphyrin
IX. Subtracting 398 nm from 700nm and sample from control wells for Femesoporphyrin IX, and 411 nm from 700 nm and sample from control for Feprotoporphyrin IX, rates of heme transfer were calculated by fitting to exponential.
Hsp90 and cell lysate proteins effect on the rate of heme transfer to apomyoglobin.
The compositions of different mixtures for each reaction well are listed below.
GAPDH human-proto heme Complex concentration into each well
14

=10 μM.

Apomyoglobin concentration into each well

=20 μM.

Cell lysate mix into each well

= 4.95 mg/ml.

Cell lysate 50k and more into each well

= 4.45 mg/ml.

Cell lysate 50k and more into each well

= undetectable.

Hsp90 alpha into each well

= 2.52 μM.

Hsp90 beta into each well

= 12.52 μM.

ATP into each well

= 1.6 mM.

2.5 GAPDH activity:
GAPDH activity was determined by measuring the changes in absorbance at 340
nm which is the absorbance for NADH. Assay mixture for activity contains 82.3
mM triethanol amine (Sigma# T9534-250g 99.5 % pure) buffer pH 7.6, 1.1 mM
ATP (Sigma# A2383-10 g), 6.2 mm glycerate 3-phosphate (Sigma# P8877-1g 99
% pure), 0.2 mM NADH (Sigma# N-8129 98% pure), 0.9 mM EDTA (Sigma#
E5134-1 kg), 2 mM MgSO4 (Sigma# M7774) and phosphoglycerate kinase (13
units/ml) (Sigma# P7634-2 ku) (14).
Kinetics of NADH disappearance was measured by using Schimadzu UV-VIS
spectrophotometer at 340 nm. 0.1-0.5 μM of GAPDH was taken into the cuvette
containing 495 μl of activity mixture and the activity was calculated by measuring
the rate of change of absorbance per minute at 340 nm, where NADH is oxidized
into NAD. 1 unit of GAPDH oxidizes 1 mole of NADH. Enzymatic activity was
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calculated from the slope and by using extinction coefficient 6.22/ M CM (NADH
at 340 nm).

2.6 Preparation of CYS-NO:
CYS-NO was prepared by taking 200 mM L-cysteine (Aldrich# 168149-25 g 97 %
pure) in 200 μM DTPA (Fluka# 32319-100 g-F.) and 200 mM HCl of 500 μl
mixed with 500 μl sodium nitrite (Sigma#s-2252-500 g) solution of 210 mM. The
solutions were mixed and incubated in the dark for 10 minutes. The pH was
adjusted to 8 with NaOH. The concentration was measured at wavelength 336 nm
by Shimadzu UV-VIS spectrophotometer by using an extinction coefficient of 900
/M CM.

2.7 Preparation of SNO-GAPDH:
500 μl of 100 μM of recombinant human GAPDH were made in 50mM HEPES,
100 mM NaCl, 75 μM DTPA, pH 7.4. 50 fold CYS-NO was added and incubated
for 30 minutes. Passed it through PD-10 columns made of G25 resin and fractions
were collected and the protein concentration was determined by measuring the
absorbance at 280 nm on a Shimadzu UV-VIS spectrophotometer by using
extinction coefficient 30000 /M CM.
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GAPDH (100uM) + Hepes
buffer (50 mM, pH 8.0) +
Cys-No (5000uM)
Incubation in the dark for 30 minutes
at room temperature

PD-10 G25 gel filtration
Collect fractions
Saville's method

Control
-Hgcl2
Total SNO= Absorbance of sample at 540nm
Fig.2.1. Schematic representation of the method to generate nitrosylated GAPDH and its
quantification.

2.8 Saville’s method:
A colorimetric assay was used for the quantification of SNO. HgCl2 displaces NO
and the NO was made to react with Griess reagent. Griess reagent includes 3.4%
W/V sulfanilamide (Sigma# S-9251.) in 0.4 M HCl and 0.1%W/V of N-(1naphthyl) ethylenediamine (NED) (Sigma# N-9125.). HgCl2 (Sigma# M-6529)
was mixed into sample and not into control. The difference between HgCl2
absorbance reading and without HgCl2 absorbance reading gives the amount of
SNO. The absorbance was measured at 540 nm. The exact procedure includes 100
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μl of nitrosylated protein sample and 50 μl 3.4% W/V sulfanilamide with HgCl2

10 mM and 50 μl 0.1% W/V of N-(1-naphthyl) ethylenediamine (NED) and
control includes the same without 10 mm HgCl2. The detection limit was 500 nM.
A summary of this method was provided in Fig.2.1.
The standard curve was made by using nitrite solution of different concentration 1
μm, 2.5 μm, 5 μm, 7.5 μm, 10 μm, 12.5 μm, 15 μm, 20 μm, 25 μm, 50 μm, 75 μm,

100 μm. The slope was calculated and by using slope, amount of SNO on protein
was calculated from the absorbance at 540 nm.

2.9 Treatment of the protein with DTT:
To reduce disulphide bonds the protein was incubated with DTT (Dithiothreitol).
In our studies for nitrosylation of proteins essentially there should not be any
disulphide bonds. We treat proteins with 10 fold excess of DTT for 1.5-2 hours
and the excess DTT is removed by passing it through PD-10 column which are
previously washed and equilibrated with buffer (32).

2.10 Effect of pH and oxygen on nitrosylation:
Degassing of buffers and reagents:
All the buffers, NaOH, DTPA solutions were degassed by using nitrogen gas for 2
hours.
Placing the materials inside Anaerobic Chamber:
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PD-10 columns, L-Cysteine, sodium nitrite, DTPA/HCL solution, Rabbit GAPDH
lyophilized powder, Human C152S mutant GAPDH, 1M NaOH, HEPES 50mM/
100 mM NaCl/75 μm DTPA buffers with pH 6, 7, 8. Griess reagent, HgCl2, 1.5 ml
centrifugal tubes, cuvettes, 96 well plates, water were placed in vacuum port for
degassing by using nitrogen gas and then in anaerobic chamber. The Cys-NO and
SNO-GAPDH was made in anaerobic chamber.
Note: Everything has to be done in the dark as SNO bond is light sensitive and
liable by light.

2.11 Preparation of GAPDH at different pH:
A solution of 100 μm Human C152S GAPDH and Rabbit wild type GAPDH were
made in 50 mM HEPES, 100 mM NACL, 75 μM DTPA in 3 different pH ranges
6, 7, and 8 by measuring concentration at wavelength 280 nm by Shimadzu UVVIS spectrophotometer by extinction coefficient 30000/M cm.

2.12 Site directed mutagenesis:
Cysteines in GAPDH were replaced with serines to identify site of nitrosylation
and its effect on heme binding and heme delivery. There are a total of 3 cysteines
in human GAPDH at 152,156 and 247 and total of 4 cysteines in rabbit GAPDH at
150, 154, 245 and 282 positions. The mutations which were considered were
single mutations C152S, C247S and double mutations C152/156S, C152/247S,
C156/247S and a triple mutant C152/156/247S in which all the cysteines were
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replaced with serines. We consider serine as replacement because serine has near
equal molecular size as cysteine. The required DNA sequencing primers were
obtained from IDT.

2.13 Polymerase chain reaction:
This is a molecular biology technique which is used for the amplification of DNA
to generate millions of copies of particular DNA sequence. It involves repeated
cycles of heating and cooling for DNA melting and DNA replication. The 2
complementary oligonucleotides which have the desired sequence or mutation
were obtained from IDT. The PCR mixture has the following 5 μl of 10X reaction
buffer, 10-20 ng ds DNA template, 125 ng of oligonucleotide primer 1, 125 ng of
oligonucleotide primer 2, 1 μl dNTP mix and make into 50 μl with ddH2O. 1μl of
pfu turbo DNA polymerase (2.5 U/ μl) was added. The dNTPs were the building
blocks from which new DNA strand is synthesized by DNA polymerase. The
quick change XL site directed mutagenesis kit was obtained from Stratagene
(Stratagene# 200517-5).
The robocycler for PCR was set up by using following the program a.) Segment 1
has 1 cycle at 950 C for 30 seconds. b.) Segment 2 has 18cycles each at 950 C for
30 seconds, 550 C for 1 minute and 680 C for 10 minutes. Segment 3 has 0 cycles
and every temperature for 0 seconds. Segment 4 has 60 C, set up for overnight, and
after reaction was done, it stays at 60 C. DPN1 was added finally to PCR mixture
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and incubated at 370 C for 2 hours to degrade template DNA, the PCR mixture
was transformed into XL 10 Gold ultra competent cells.

2.14 Transformation into XL10-Gold ultra competent cells:
The XL10 Gold ultra competent cells (Cat# 200315) were obtained from
stratagene. Two 14 ml BD falcon tubes were chilled on ice and NZY broth was
heated to 420 C. The XL-10 cells were thawed on ice and 50 μl of cells placed in
each of the tubes and add 4 μl 2ME, swirl every 2 minutes for 10 minutes by
placing on ice. 2 μl of PCR mixture was added and incubated on ice for 30
minutes, Heated in water bath at 420 C, incubated on ice for 2 minutes. 0.5 ml
preheated NZY broth was added to the mixture and incubated at 370 C for 1 hour
shaking at 250 rpm. 250 μl of cells were plated on pre warmed LB-Amp agar
plates and incubate overnight at 370 C. The colonies were sequenced to confirm
the presence of mutation.

2.15 DNA purification:
Up to 6 colonies were picked from each plate and grown in LB-Amp overnight.
The cells were harvested in 6 different centrifugal tubes by spinning down at
13000 rpm for 2-3 minutes and the supernatant was discarded. Cells were
suspended in 250 μl P1 buffer to which RNase was added previously. 250 μl P2
buffer was added and mixed, 350 μl N3 buffer which is neutralization buffer was
added and mixed. Centrifuged for 10 minutes at 13000 rpm and supernatant was
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applied to QIA prep spin column and flow through was discarded as our plasmid
DNA was bound to column. Washed with 0.75 ml washing PE buffer and
centrifuged for 60 seconds. Flow through was discarded and centrifuged for 1
minute to remove any remaining PE buffer. The last step was the elution of the
DNA. Clean autoclaved 1.5 ml centrifugal tubes were taken and QIA prep column
(Qiagen# 27106) was placed into them, 50 μl elution buffer was added to column
and centrifuged for 1 minute. The plasmid DNA was eluted into centrifugal tube.

2.16 Transforming DNA into over expressing cells:
The plasmid DNA carrying the desired mutation was transformed into over
expressing BL-21 cells. 1.5 ml C-medium was heated to 370 C and 0.15 ml of
overnight culture was added to 1.5 ml C-medium which was at 370 C and left in
shaker for 20 minutes at 370 C. Transform aid T-solution was prepared by mixing
250 μl of T-solution (A) and 250 μl T-solution (B) (Fermentas# K2711). The
culture (C-medium) was spun down at 13000 rpm for 2 minutes and the pellet was
suspended in 300 μl transform aid T-solution, incubated on ice for 5 minutes.
Centrifuged, supernatant was removed and 120 μl transform aid T-solution was
added and incubated on ice for 5 minutes. 1 μl DNA was added into 50 μl cells in
transform aid T-solution and incubated on ice for 5 minutes. Cells were plated on
LB-Amp agar plates which were pre warmed at 370 C and incubated overnight at
370 C, control was performed by plating 50 μl cells from transform aid T-solution
without adding plasmid DNA on to LB-Amp agar plates, colonies were picked
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from the LB-Amp agar (no colonies on control.) and were grown in LB-Amp.
Stocks were made by using 500 μl 50% sterilized glycerol and 500 μl culture and
were stored at -800 C.

2.17 Checking the protein expression of different mutants of GAPDH:
To check the protein expression, 3 individual colonies from each mutant GAPDH
LB-Amp agar plate were selected and grown in 20 ml LB-Amp for 12-16 hours.
The cells were pelleted by spinning at 5000 rpm at 40 C for 10-15 minutes. For
each 100 mg pellet 200 μl B-PER (bacterial protein extraction reagent) (PDT#
90084 thermo scientific) was added, cells were pipetted with B-PER until it is
homogeneous, incubated for 15-20 minutes at 40 C. Centrifuged at 15000 rpm for
5 minutes, our protein of interest is cytosolic protein and hence remains in
supernatant. Supernatant was incubated with GST beads for 2 hours, GST beads
(Pharmacia biotech# 17-0756-01) were washed with 1XPBS to remove unbound
proteins which does not have GST, GST with GAPDH remains with the GST
beads. The GST beads were then eluted with GSH (Sigma#G-4251) containing
buffer and now GST with GAPDH was present in Buffer. Protein concentration
was determined for this protein in buffer. The colony which expresses maximum
protein of our interest is further used for purification in larger batches. Protein
expression was determined by western blotting by using Anti-GST, since GAPDH
which we use has a GST tag, so the band shows at around 60 KDa. Depending on
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the intensity of the signal, colony that expresses optimum levels of protein of
interest was selected.

2.18 Purification of myoglobin mutant:
Myoglobin mutant from sperm whale myoglobin was purified from a stock culture
of E.coli strain ER2566 (NEB) and plasmid with pUC19 vector. 100 ml LB with
125 μg/ml ampicillin was inoculated with stock culture, grown overnight at 370 C,
shaking at 250 rpm. 4 liters terrific broth with 125 μg/ml ampicillin was divided
into 8 flasks and into each flask 10 ml of overnight culture is inoculated and
shaken at 370 C for 1.5-2 hours and once stationary phase is reached which is
measured at 600 nm by using spectrophotometer optical density should be around
0.8 to 1, the cells were spin down at 6500 rpm for 20 minutes at 40 C. The pellets
if not used immediately were kept frozen at -800 C till use. The cell pellets were
thawed and resuspended in 100ml lysis buffer which was made of 50 mM Tris
HCl pH 8.0, 1 mM EDTA, 0.5 mM DTT, 0.5 mM DTT, 5 unit/ml DNase, 1 mg/ml
lysozyme, PI#1 (5 mg/ml Aprotinin, 1 mg/ml Leupetin), PI#2 (1 mg/ml Pepstain
A, 24 mg/ml Pefabloc SC in DMSO) and 1 μM PMSF and left on ice for 30
minutes. The cell suspension was sonicated at 36% amplitude for 35 seconds for 3
times. The sonicated cell suspension was centrifuged at 20000 rpm for 45 minutes
at 40 C to remove cell debris. The supernatant was brought to 60% ammonium
sulfate saturation slowly; after 60% saturation was reached the solution was
allowed to sit at 40 C for 2 hours. The 60% saturated solution was centrifuged at
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20000rpm for 30 minutes to remove precipitate, supernatant was then made to
saturate with ammonium sulfate till 95%. The precipitate was collected by
centrifugation at 20000 rpm at 40 C for 30 minutes, stored at -800 C till use. The
precipitate from ammonium sulfate precipitation was resuspended in 30 ml 50 mM
Tris HCl pH 8.0, 2 M Ammonium Sulfate and centrifuged again at 20000 rpm for
30 minutes at 40 C to remove any pellet, supernatant was loaded onto phenyl
sepharose column which was previously equilibrated with 50 mM Tris HCl pH
8.0, 2 M Ammonium Sulfate. Column was equilibrated with 3-4 column washes of
50 mM Tris HCl pH 8.0, 2 M Ammonium Sulfate. Elute myoglobin with 2 column
volumes of 20:80 ratio of 50 mM Tris HCl pH 8.0, 2 M Ammonium Sulfate (20):
50 mM Tris HCl pH 8.0 (80). Collected fractions were dialyzed against 50 mM
Tris HCl pH 8.0 with 1 buffer change. Dialyzed sample was passed through the
DE-52 column which was equilibrated with 50 mM Tris HCl pH 8.0 and the flow
through was collected. Myoglobin was concentrated to 1mM (17).
0.3 ml of the concentrated myoglobin solution was placed in 2-3 microcentrifuge
tubes and place on ice. 100-300 μl of 0.1 M HCl was added to adjust pH to 2.32.5, 0.4 ml cold methyl ethyl ketone was immediately added to each of the tubes
and the solution was left on ice for 1 minute and centrifuged for 2 minutes to
separate 2 phases. The organic phase was removed and the process was done until
there was no visible heme. The aliquots were combined and dialyzed against cold
water for 4 to 6 hours and repeated for 3 to 4 times. The samples were lyophilized
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and stored at -800 C. The samples were reconstituted with buffer and concentration
was measured at 280nm by using extinction coefficient 15200 /M CM.

2.19 Purification of GAPDH:
500 ml of LB was inoculated with glycerol stock of GAPDH and 1 ul/ml of
ampicillin was added, incubated at 370 C with shaking at 250 rpm for 14 to 16
hours. 50 ml of grown culture was transferred into 500 ml TB with 1ul/ml
ampicillin and incubated at 370 C with shaking at 250 rpm until optical density
reaches 0.8 to 1. The cultures were induced with 1 mm IPTG and the cultures were
left shaking at 250 rpm for 48 hours at room temperature. Cells were spun down at
7000 rpm at 40 C for 30 minutes. Supernatant was discarded and the cell pellets
were stored at -800 C until used. Lysis buffer was prepared using 100 ml PBS, 0.5
mm EDTA, 1 mg/ml lysozyme, 1 mm PMSF/DMSO, PI#1, PI#2. Pellet was
thawed using 10 to 13 ml lysis buffer and gently suspended. Suspension was
sonicated for 35 seconds at 36% amplitude by altered pulses for 7 seconds. This
step was repeated for 3 to 4 times until the suspension become thinner and darker.
The suspension was centrifuged at 18,000 rpm for 1 hour and the supernatant was
collected, incubated with GST sepharose resin for 2 hours at 40 C. The GST
sepharose resin was prepared by washing and equilibrating with 1XPBS. GST
sepharose resin was spun down at 600 rpm for 3 minutes at 40 C and thick
supernatant was discarded, as the desired protein was bound attached to GST
sepharose resin. This step was repeated by adding 1XPBS and for 2 to 3 times, and
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PBS with resin was added to column. For elution, buffer with 100 mm Tris-HCL
pH 8, 10 mm GSH was prepared. Elution buffer was added to the column having
the GST resin and agitated for 1-2 minutes and the flow through was collected.
This step was repeated for 2 to 3 times to collect all the GST bound protein. The
collected protein was concentrated using Amicon 30 K concentrator to 2-3 ml and
washed with 1XPBS with 3 mm DTT and concentrated to 2 to 3 ml again.
Thrombin (10 unit/mg 50 ul) was added to this concentrated protein which cleaves
the GST tag from protein, incubated at 370 C for 2 hours, the protein with
thrombin was incubated with GST resin at 40 C for 2 hours to remove any protein
which has GST tag, flow through was collected. The protein was then passed
through Benzamidine FF resin (GE heath care#17-5123-10) which has been
previously equilibrated with 50 mm Tris HCl and 500 mm NaCl, pH 8 to remove
excess thrombin. The protein was concentrated to 2 to 3 ml by using Amicon 30 K
concentrator, washed with 50 mm Tris pH 8 150 mm NaCl, 20% glycerol (Fisher
bio reagents# BP229-4) for 2 to 3 times and was concentrated to 2 to 3 ml. To
determine the purity SDS-PAGE was performed, our desired protein (GAPDH)
has molecular weight of 37 KDa approximately (11).

2.20 SDS-PAGE:
SDS-PAGE was used to separate proteins by their molecular weight. The lower
gel (separating gel) was made by using 5.6 ml 30% acrylamide (National
diagnostics# EC-890), 5 ml 1.5 M Tris (Sigma# T1503-1 kg 99.9% pure), pH 8.8
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with SDS (CAL Biochem# 428015), 9.1 ml water, 100 μl of 10% APS
(Amresco#K833-100tabs), TEMED (Sigma# T9281-50ml) 20 μl, which indicates
the separating gel is a 8.5%. The upper gel (stacking gel) was prepared using 1.3
ml 30% acrylamide, 2.5 ml 0.5 M Tris pH 6.8 with SDS, 6.1 ml water, 50 μl 10%
APS, 20 μl TEMED. Samples were mixed with sample buffer which consists of
glycerol, SDS, 2-mercaptoethanol (Sigma# M-3148), bromophenol blue and
water, boiled for 5 minutes at 950 C and were cooled down to room temperature.
The protein samples were then loaded onto the gel. Non- reducing sample buffer
which has no 2-mercaptoethanol was used for mass spectrometry experiments,
where the protein samples were reduced during mass spectrometry sample
digestion. The gel electrophoresis was performed at 90-100 V. Once the
electrophoresis was finished, the gel was removed and stained with coomassie
blue for 1 hour and destained using 30% methanol and 7% acetic acid overnight.
The protein was identified by the blue bands and the molecular weight was
determined using commercially available standards (Precision blue protein marker
from Bio-Rad# 161-0373).

2.21 Western blotting technique:
It is a widely used technique to detect the specific protein or the protein of interest.
This is also known as immunoblotting as it uses specific antibodies to detect the
specific protein. After the gel electrophoresis was done, gel was washed with
water for 10 minutes and equilibrated with semidry transfer buffer. The PVDF
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membrane of size of gel was cut and activated with methanol, blotting sheet was
equilibrated with semidry transfer buffer. The equilibrated blotting sheet was
placed on transfer apparatus and then PVDF membrane, followed by gel and
finally with one more equilibrated blotting sheet. Air bubbles should be avoided.
Transfer was done for 40 minutes at 6 amperes current. The proteins were then
transferred onto PVDF membrane. The blocking of PVDF membrane was done by
using 5% non fat dry milk in PBS mixed with tween 20 overnight. The blocked
PVDF membrane was incubated with primary antibody which was made by
diluting antibody in 5% non fat milk for an hour at room temperature. The PVDF
membrane was then washed with PBST for 3 times and incubated with secondary
antibody for 1hour and then washed with PBST for 3 times and finally washed
with PBS before adding substrate. ECL kit which is enhanced chemiluminescence
was used for detecting secondary antibody which in turn gives signal about
primary antibody and the primary antibody is specific for each protein. The
detection solutions A and B were mixed in ratio of 40:1 on PVDF membrane after
secondary antibody and washing steps, incubated for 5 minutes and after 5
minutes excess detection reagent was drained out and the PVDF membrane was
placed on a cassette by placing it inside a wrap and the interface should be black.
Expose Kodak scientific imaging film on the wrapped PVDF membrane in the
dark. Film was developed. The signal was seen as dark band. The intensity of the
signal is proportional to the amount of protein in the original sample. In biotin
switch technique only one antibody was used which is biotin antibody which is
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HRP conjugated and directly interacts with biotin. Here after blocking with milk
wash PVDF with PBST and then finally with PBS followed by incubation with
biotin antibody for 1.5 to 2 hours. Then ECL technique was used as previously
described and Kodak scientific imaging film is used to detect the
chemiluminescence signal which is due to substrate bound to HRP conjugated
antibody which in turn indicates the specific protein.

Reaction with
ECLECL

with ECL

Fig.2.2. Schematic representation of Western blot technique.
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2.22 Estimation of the extent of nitrosylation by SNOB reagent using western
blot:
Stock concentration of 10.6 mm was prepared by dissolving 1.5 mg of SNOB
reagent (Tocris# 3879) and SNOB control (Tocris# 3880) in 50 μl of DMSO, then
dissolved in 500 μl PBS, stored at -200 C. The stocks were stable for a month in
the dark at -200 C. Nitrosylation of the protein was carried out as previously
described. 50 μm of nitrosylated and non nitrosylated GAPDH was treated with 20
fold excess of SNOB reagent and control for 30 minutes at 600 C or 2-3 minutes
exposing to high intensity light and excess SNOB was removed by passing
through the PD-10 columns. The concentration of protein was determined and the
same amount of protein was loaded into the gel with non-reducing sample buffer
and gel electrophoresis was performed. After the gel was done the electrophoresed
proteins were transferred onto PVDF membrane and immunoblotted using a biotin
antibody. Mechanism of working of SNOB reagent was represented below.

Fig.2.3. Reaction of the SNOB reagent with nitrosylated protein.
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2.23 Sample preparation for mass spectrometry to determine the extent of
nitrosylation on each individual cysteine:
Human and rabbit GAPDH were nitrosylated as previously described. 50 μm of
200 μl GAPDH were taken and 50 mm of 400 μl of NEM was added, incubated at
room temperature for 1.5 to 2 hours. Excess NEM (Thermo scientific# 23030) was
removed by acetone precipitations which was done by adding 20 volumes prechilled acetone to protein and incubated at -200 C for 20 minutes, centrifuged at
minimum of 2000 rpm for 10 minutes, precipitate was dissolved in 100 μl Hepes
buffer with 1% SDS. 4 mM of 300 μl biotin HPDP (Pierce net# 21341) and 50
mM ascorbate solution was added to this dissolved protein. The samples were then
mixed with non-reducing sample buffer and loaded onto gel and gel
electrophoresis was performed. The staining was done using the gel code blue
reagent, for overnight and then samples were subjected for mass spectrometric
analysis.
Biotin HPDP was replaced with alkylating agent iodoacetamide (Acros organics#
AC12227-0050), since we got very less biotinylation, when compared to

nitrosylation with Saville’s method. In iodoacetamide method after acetone
precipitation, protein was dissolved in HENS buffer and 10 mm DTT for 100 μm
protein, incubated for 2 to 3 hours. Iodoacetamide was added in excess which is 4
to 5 fold excess of DTT as DTT reacts with iodo acetamide and incubated for 2
hours. Proteins were mixed with sample buffer which is non-reducing with no
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boiling and loaded onto gel and gel electrophoresis was performed. The gel was
stained with gel code blue (Thermo#24592) and subjected to mass spectrometry.
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CHAPTER III
RESULTS AND DISCUSSION

3.1 Characterization of Heme transfer reactions using GAPDH-heme to
apomyoglobin as a model:
My project focuses on kinetics of heme dissociation from the GAPDH-heme
complex which is measured by the rate of heme binding to apomyoglobin. This
was measured by the absorbance changes occurring at 410nm with time for protoheme and at 398nm for meso-heme.
The typical spectrum of the GAPDH-heme complex looks like below after passing
the GAPDH-heme complex through PD-10 columns where free heme was
removed and only heme bound to GAPDH was eluted. Typical ratio of heme
bound to GAPDH is 0.5 heme to 1 monomer GAPDH.
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Fig.3.1. UV-Vis spectrum of heme bound GAPDH. The near 400nm peak represents heme bound
to GAPDH peak and the wavelength maximum at 280nm represents GAPDH peak.

A typical time course for the transfer of heme from GAPDH to apomyoglobin was
shown in Fig.3. 2. The rate difference was monitored by spectral changes against
time.
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Fig.3.2.1 Typical curve for meso heme transfer from GAPDH-heme complex to apomyoglobin.
The monitored wavelength is 398nm for meso-heme.

Fig.3.2.2 Typical curve for proto heme transfer from GAPDH-heme complex to apomyoglobin.
The monitored wavelength is 411nm for proto-heme
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The rates of heme transfer were different for 2 heme types which were considered
here. The 2 types of heme which are considered here are meso and proto heme.
The rate of heme delivery was 2 times faster for meso heme compared to that of
proto heme which is shown in the Fig.3.3. Meso heme differs from proto heme in
the side chain.

Fig.3.3. In the above graph red column represents meso heme which shows that it has faster rate
of heme delivery compared to that of proto heme which is represented by black column.

The rate of heme transfer from GAPDH-meso heme complex is faster to
apomyoglobin, compared to the rate of heme transfer from GAPDH-proto heme
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complex. The reason may be that, meso heme is less strongly bound to GAPDH,
when compared to binding of proto heme to GAPDH.
We focused on factors affecting the rate of heme transfer.
Effect of GAPDH-Heme complex concentration on rate of heme transfer to
apomyoglobin:
We examined if GAPDH-heme complex concentration has any effect on heme
uptake by apomyoglobin by maintaining same ratio of complex to apomyoglobin
ratio. GAPDH-heme complex was used in different concentrations in each well
and apomyoglobin added was 3 fold excess to that of heme concentration.
Changing the concentration of complex has no effect on rate of heme transfer to
apomyoglobin, as shown in Fig.3.4.

Fig.3.4. Comparing different amount of GAPDH-heme complex to same fold of apomyoglobin.
As the results show it has no substantial effect on rate of heme transfer.
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Effect of heme: GAPDH ratio on the rate of heme transfer to apomyoglobin:
We examined if the amount of heme bound to GAPDH influences the rate of heme
transfer to apomyoglobin. GAPDH-heme complexes were prepared considering
100uM GAPDH as constant and increasing heme concentrations from 100uM,
200uM, 400uM, 800uM and passed them through PD-10 gel filtration columns to
remove free heme. Same protein concentration, different heme concentration and
maintained same apomyoglobin: heme ratio was maintained in each well. The
results from this experiment suggest that the rate of heme uptake by apomyoglobin
is independent of amount of heme bound to GAPDH.

Fig.3.5. Comparison of rates of heme transfer when different amount of Heme placed into each
well maintaining GAPDH same. The results show that there was not much substantial difference
in rate of heme transfer.
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3 complexes were made with same GAPDH concentration and with different heme
concentrations. Same amount of heme and apomyoglobin were loaded into each
individual well. Here the variable was GAPDH. The effect seems to be increasing
as GAPDH is decreasing but it’s less than 20% which is with in the experimental
error range.

10 µM

12.5 µM

20 µM

Amount
of GAPDH
Amount
of
Fig.3.6. Comparison of rate of heme transfer when different amount of GAPDH is placed into
well by maintaining same amount of heme into final well. The result shows that the effect is not
substantial, although it shows that rate is increasing with lowering amount of GAPDH.

Effect of NO on the rate of heme transfer from GAPDH to apomyoglobin:
We examined if any external factors has an affect on rate of heme uptake by
apomyoglobin. We here focused on NO as it has many physiological roles, since
specific nitrosylation of GAPDH at cysteine 152 was shown to block cellular
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heme insertion into iNOS (9). The first experiment which was considered was
adding NO donor GSNO to GAPDH-heme complex incubating less than 5
minutes before adding apomyoglobin. As shown below here there is no substantial
effect of NO on rate of heme delivery.
.

Fig.3.7. Comparison of rate of heme transfer from GAPDH-heme complex to that of GAPDHheme complex with nitrosylation donor added to it before adding apomyoglobin. . The result
shows that S-nitrosylation of GAPDH has no effect on the rate of heme transfer.

Effect of Hsp90 and cell lysate proteins on rate of heme transfer from GAPDHheme complex to apomyoglobin:
We examined if Hsp90 has an affect on rate of heme transfer, which is a
chaperone and is believed to have an involvement in heme insertion into a number
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of proteins (8). Cell lysate fractions of human macrophages were prepared, rate of
heme transfer to apomyoglobin from GAPDH-heme complex were compared to
that of GAPDH-heme complex mixed with macrophage cell lysate and Hsp90.
The results suggest that Hsp90, cell lysate proteins does not affect the rate of heme
transfer. We maintained same GAPDH-heme complex to apomyoglobin ratio.
contents

value 1

value 2

average

a.) Apomyoglobin+ complex

8.999x 10-4

1.02x 10-3

9.599x10-4

b.) Apo+ complex + cell lysate mix

1.29x10-3

1.13x10-3

1.21x10-3

c.) Apo+ complex+ 50k and more

1.23x10-3

1.41x10-3

1.32x10-3

d.) Apo+ complex+ 50k and less

1.02x10-3

7.924x10-4

9.062x10-4

e.)Apo+ complex+ cell lysate mix+ HSP90

1.60x10-3

1.02x10-3

1.31x10-3

f.) Apo+ complex+ HSP90

1.48x10-3

1.10x10-3

1.29x10-3

g.) Apo+ complex+ 50k and more+ HSP90

1.16x10-3

1.19x10-3

1.175x10-3

h.) Apo+ complex+ 50k and less+ HSP90

1.06x10-3

1.06x10-3

Table 3.1. The Koff values for each different combination were represented in the table 3.1.
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Fig.3 8. The above figure shows the effect of Hsp90 and macrophage cell lysate on heme transfer
of GAPDH-heme complex. It shows very slight increase in rate of heme transfer when Hsp90 and
also with macrophage cell lysate of 50kda and high compared to GAPDH-heme complex.

Effect of different doses of cell lysate on rate of heme transfer from GAPDHheme complex to apomyoglobin:
We examined dose response curve of cell lysate with maintaining same
concentration of GAPDH-heme complex and apomyoglobin and the only variable
is cell lysate protein concentration. No substantial change was observed on the
rates of heme transfer with varying concentrations of cell lysate.
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Fig.3.9. Comparison of rate of heme transfer when different concentration of macrophage cell
lysate added to GAPDH-heme complex. The result shows that there was no substantial effect on
rate with amount of cell lysate.
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3.2 Tryptophan quenching:
This is used to check the binding between 2 proteins or 2 ligands. Here we tested
the binding between different GAPDH with heme. Fig.3.10 shows a representative
titration quenching experiment with different doses of heme. The result shows that
there was strong binding between rabbit GAPDH and heme when compared with
human GAPDH. The mutants show that there was not much difference in amount
or strength of binding compared to human wild type. The mutants which we
considered here were cysteine 152 and lysine 227 which were available in lab.

Fig.3.10. Above graph shows the quenching of fluorescence when adding increasing amounts of
heme to GAPDH.
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Fig.3.11. Above graph shows that rabbit GAPDH has more affinity towards heme compared to
human GAPDH and there is no substantial difference between different mutants of human
GAPDH although lysine 227 mutants appears to have slightly more competent binding.
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3.3 S-Nitrosylation of GAPDH, its effect on activity and rate of heme delivery:
Previous work from our lab (9) has shown that by nitrosylating GAPDH the heme
binding capacity of GAPDH was reduced. Based on this finding, I set out to
investigate the effect of S-nitrosylation on the ability of GAPDH to transfer its
heme into apomyoglobin. GSNO was used as NO donor to nitrosylate the
GAPDH. The amount of nitrosylation is determined by the Saville’s method which
uses the Griess reagents. The activity is also used to check the nitrosylation of
cysteine 152 as it is the active residue in GAPDH. GAPDH was nitrosylated as per
the published protocol and the activity assay was performed before and after
nitrosylation and also after incubation with heme. We also determined the rate of
heme transfer to check the effect of nitrosylation on heme transfer of GAPDH.
The results are shown in Fig.3.12.

Fig.3.12. The graph shows that there was decrease in activity as protein gets nitrosylated. The
heme does not have any significant decrease in activity.

47

As shown in the above graph there was a decrease in GAPDH activity upon
nitrosylation, addition of heme had no effect on GAPDH activity.
Then, as described above, we measured the rates of heme transfer under these
conditions. Similar rates were obtained for nitrosylated and non-nitrosylated
proteins. . The extent of nitrosylation of our GAPDH preparation is determined by
Saville’s method. The level of nitrosylation under these conditions was very less
(~15%). Dose response curve was performed to increase the extent of
nitrosylation. No improvement in the extent of nitrosylation was obtained.

3.4 Nitrosylation and factors affecting the nitrosylation:
Physiological NO donor Cys-NO was used, which was prepared in laboratory by
mixing sodium nitrite and L-cysteine with DTPA as described in method. We used
bovine serum albumin to check the amount of nitrosylation as BSA was less
expensive and easily available. Range of concentration of Cys-NO 10, 20, 30 and
up to 150 fold was used with respect to protein concentration, low levels of
nitrosylation (~30%) was obtained. Freshly prepared BSA and frozen BSA was
treated with 100-fold excess DTT to check if any disulphide bonds present are
interfering with extent of nitrosylation and excess DTT was removed by PD-10
columns. There was dramatic increase in the levels of nitrosylation by reducing
BSA with DTT both in fresh as well as frozen samples. A similar finding was
reported previously (33).
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Fig.3.13. The difference in amount of nitrosylation of normal BSA and DTT treated BSA. The
result shows that it has a substantial difference in amount of nitrosylation which indicates that the
presence of disulphide bonds was interfering with the process of nitrosylation.

GAPDH was reduced with 100 fold excess DTT to check if any disulphide bonds
are interfering with extent of nitrosylation. DTT treated and untreated GAPDH
shows same amount of nitrosylation after nitrosylating with Cys-NO. The result
suggests that there was no effect of DTT indicating that there were no disulphide
bonds and dose 20 fold of nitrosylation donor shows having better nitrosylation.
We examined other factors which may have effect on nitrosylation of GAPDH like
dose of NO donor and presence of reducing agents (example: DTT). Nitrosylation
is light sensitive. Range of concentrations 10, 20, 50, 200 fold Cys-NO to that of
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GAPDH was considered. The result suggests that there were no disulphide bonds
which are interfering with nitrosylation and nitrosylation is not dose dependent.

Fig.3.14. The amount of nitrosylation happening with increasing amount of nitrosylation donor
and comparison with and with out adding DTT. The result suggests that there is no substantial
difference on extent of nitrosylation.

We focused on dose response curve of different GAPDH to understand the affect
of amount of nitrosylation donor on extent of nitrosylation on human recombinant
wild-type GAPDH, c152s mutant human GAPDH and rabbit muscle GAPDH.

3.5 Dose response curves for S-nitrosylation of different GAPDH variants:
Rabbit GAPDH:
In case of rabbit GAPDH, the result shows no effect of dose of nitrosylation donor
on extent of nitrosylation (Fig.3.15). The fold of Cys-NO which was considered,
was 1, 2, 3, 5, and 10, 20 and 50-fold to that of protein concentration
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Fig.3.15. Comparing different doses of nitrosylation donor with same amount of rabbit muscle
GAPDH. The results show that there was no substantial effect on the extent of nitrosylation
though slightly higher nitrosylation was observed at 20 fold.

Human GAPDH:
In the case of human GAPDH the extent of nitrosylation is directly proportional to
Cys-NO fold (Fig.3.15). The amount of nitrosylation was increased with amount
of Cys-NO used. The fold of Cys-NO which were considered, were 1, 2, 3, 5, 10,
20 and 50 fold to that of protein concentration.
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Fig.3.16. Comparing different doses of nitrosylation donor with same amount of Human
GAPDH. The result shows that the nitrosylation is increasing with the amount of nitrosylation
donor which shows that it has maximum effect at 50fold.

C152s GAPDH:
In the case of human C152S mutant GAPDH the extent of nitrosylation was
directly proportional to Cys-NO fold. Surprisingly, we found that the extent of
nitrosylation was similar to human wild-type GAPDH, in vivo experiments from
our lab suggests that nitrosylation occurs only at cysteine 152, here with out
cysteine 152 similar extent of nitrosylation was observed. Possibilities include that
S-nitrosylation is specific in vivo, which was not observed in vitro. Protein DNA
sequencing was performed to confirm the presence of mutation. Wild type has the
activity and C152S has none, as expected.
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SNO per 1 µM monomer
SNO per 1 µM monomer
SNO per 1 µM monomer

Fig.3.17. Comparing different doses of nitrosylation donor with same amount of Human c152s
GAPDH, the result shows that the nitrosylation is increasing with the amount of nitrosylation
donor which shows that it has maximum effect at 50fold.

3.6 Stability of nitrosylated GAPDH:
We examined the stability of nitrosylated GAPDH with time and the effect of
heme on stability of nitrosylated GAPDH. GAPDH was nitrosylated using 50-fold
excess Cys-NO. The stability tests were conducted at 0, 2, 6, 18, 48, 72, 120
hours. Stability test for nitrosylated-GAPDH was performed at two conditions:
room temperature and 4oC. We took both rabbit GAPDH and human GAPDH to
compare the results.
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Fig.3.18.The amount of nitrosylation at different time points at room temperature and 4 degree
centigrade with and without heme. As the time progresses the amount of nitrosylation decreases
which is drastic at room temperature and less at 4 degree centigrade. The proteins which were
considered here are human and rabbit GAPDH and the nitrosylation donor used was 50 fold.

From the above graph (Fig.3.18) it is observed that levels of nitrosylation
decreased with time and at room temperature the nitrosylation drops down
drastically. Human GAPDH at 4oC is stable for up to 5 days the presence of heme
does not have any effect on the stability of rabbit and human nitrosylated GAPDH.
From the above experiment one thing that is confirmed is that temperature plays
major role in the stability of nitrosylated GAPDH besides light.
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Effect of pH on S-nitrosylation of GAPDH:
The other factor which I considered was the pH as we are utilizing a dose of 50fold excess Cys-NO to that of protein concentration. Here the pH’s which I
considered was near physiological pH’s which are 6, 7, and 8.The effect was
found to be as the pH increases the nitrosylation of GAPDH increases in case of
rabbit and in case of human it is shown to have increased yields of nitrosylation at
acidic and alkaline and remain less at neutral pH at 7. Here 3 buffers of different
pH were made and GAPDH solutions were made with those buffers. Then 50fold
Cys-NO was added and rest is as usual and PD-10 columns were also equilibrated
with respective buffers. Altogether, these results suggest that human and rabbit
GAPDH present differences in their ability to undergo S-nitrosylation at different
pH’s, which may be due to the extra exposed cysteine present at 282 position in
rabbit GAPDH.

Fig.3.19. Comparing the amount of nitrosylation on rabbit muscle GAPDH which are nitrosylated
at 3 different pH 6, 7 and 8. The result shows that the degree of nitrosylation slightly increases
with increase in pH which shows maximum nitrosylation at pH 8.
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Fig.3.20. Comparing the amount of nitrosylation on human GAPDH which were nitrosylated at 3
different pH’s 6, 7 and 8. The result shows that the degree of nitrosylation is independent of pH.

Effect of oxygen on the efficiency of S-nitrosylation of GAPDH:
We examined the affect of oxygen on extent of nitrosylation (As oxygen can cause
free thiol oxidation). Nitrosylation was performed in anaerobic chamber to
determine the affect of oxygen on extent of nitrosylation of GAPDH. All the
buffers and reagents and also PD-10 columns were degassed by using nitrogen
prior to experiment. We considered 3 different pH’s 6, 7 and 8. The result from
Fig.3.21, which when compared to Fig.3.20 suggests that there were no oxidized
cysteines in human GAPDH. A comparison of aerobic and anaerobic conditions
shows no difference in the yield of nitrosylation.

56

Fig.3.21. Comparing the amount of nitrosylation on human GAPDH in absence of oxygen which
were nitrosylated at 3 different pH 6, 7 and 8. The result shows that the amount of nitrosylation is
independent of pH and oxygen.

Finally, we considered whether or not the use of HEPES buffer was most
appropriate for these experiments. Although not previously reported we suspected
that tertiary amines may interfere with nitrosylation by reacting with Cys-NO. We
also checked PD-10 column effectiveness in terms of removing unreacted CysNO. So here we incubated HEPES with 50ul which generally is 50fold or more
when considered protein for 30-45 minutes and passed it through the PD-10
columns and found negligible amount of NO. By this experiment we confirmed,
HEPES buffer has no effect on S-nitrosylation and PD-10 gel filtration columns
blocks unreacted NO donor.
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3.7 Estimation of the extent of s-nitrosylation on each individual cysteine by
mass spectrometry:
Extent of nitrosylation on each individual cysteine residue was identified by mass
spectrometry as we have seen C152S mutant GAPDH was getting nitrosylated,
which was different from in vivo data. SNOB technology was used as this is a
single step reaction which directly involves labeling with SNOB reagent without
using any free thiol blocker and ascorbate to reduce and acetone precipitation steps
as in case of biotin switch technique.
The result in Fig. 3.22 represents that SNOB reagent reacts with both nitrosylated
and non-nitrosylated GAPDH and SNOB control does not react.

GAPDH

Fig.3.22. The immunoblotting representing SNOB reagent and control. Human wild type and
human C152S mutant GAPDH nitrosylated and non nitrosylated were mixed with SNOB reagent
and control at 60 degree centigrade and immunoblotted. The result shows that the SNOB reagent
or the control has no specificity for nitrosylated and non nitrosylated GAPDH.
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The result in Fig. 3.22 represents that SNOB reagent reacts with both nitrosylated
and non-nitrosylated GAPDH and SNOB control does not react. Different
conditions were examined, where only nitrosylated GAPDH reacts with SNOB
reagent. SNOB was reacted with nitrosylated and non-nitrosylated GAPDH 60o C
for 30 minutes, 40o C for 30 minutes and exposed to high intensity light for 2-3
minutes [The patent document for use of SNOB reagent suggested to test 2
temperatures]. Same concentration of protein was loaded onto each well in gel.
The result below shows that SNOB technology has no specificity for nitrosylated
and non-nitrosylated GAPDH.
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Fig.3.23. The immunoblotting representing SNOB reagent and control. Human wild type and
human C152S mutant GAPDH nitrosylated and non nitrosylated were mixed with SNOB reagent
and control at 3 different conditions 60 degree centigrade, 40 degree centigrade and high beam
light for 2 minutes and immunoblotted. The result shows that the SNOB reagent or the control
has no specificity for nitrosylated versus non nitrosylated GAPDH.

Biotin switch technique was used to identify the extent of nitrosylation on each
individual

cysteine

with

little

modification;

MMTS

(methyl

methane

thiosulfonate) was replaced with NEM (N-ethylmaleimide). Biotin-HPDP was
used as labeling agent; quantification of biotin-HPDP was done by mass
spectrometry. Human GAPDH and rabbit GAPDH were used. The sample buffer
used here is non-reducing buffer with no boiling. Same amount of sample was
loaded onto each well. The controls used here was non-nitrosylated GAPDH. The
gel electrophoresis was done until protein bands get separated. The gel is then
subjected to mass spec analysis. Of the four cysteines in rabbit GAPDH three were
identified and the cysteine at 282 was not identified. In human GAPDH 3
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cysteines were identified in the Carbamidomethylated, NEM, and biotin modified
form.
1.) Human GAPDH: C152, C156, and C247.
The T146-162 peptide, IISNASCTTNCLAPLAK, contains the Cys150 and
Cys152

residues

and

was

identified

in

several

forms

including

the

carbamidomethylated, NEM, and biotin modified form. The only biotin form of
the IISNASCTTNCLAPLAK peptide identified in these experiments was the
C+559 form. The C247 peptide, VPTANVSVVDLTCR, was also identified in the
carbamidomethylated, NEM, biotin 559, and biotin 525 forms.
-While three sites of C+Biotin were identified in these bands, ratios of the
CBiotin/ (CNEM+C) may be giving a first estimation to the degree of
modification

at

these

sites.

These

ratios

for

human

GAPDH

Cys152:Cys156:Cys247 are 0.0021:0.0003:0.0017 indicating that the preference
of NO modification is Cys152 ~ Cys247 > Cys156
2.) Rabbit GAPDH: C150, C154, and C245.
The results from the rabbit samples were very similar to the human samples with
each Cys Residue identified in the C, CNEM, and CBiotin forms. While both
C150 and Cys154 were identified in the biotinatlyed (559) form Cys150 appears to
be modified to a greater extent than Cys154. In addition, only the Cys150 residue
was identified in the CBiotin (525) form. The Cys245 residue was also identified
in all four forms. Consistent with the results of human GAPDH the C+525 Da
form is almost an order of magnitude lower in abundance than the C+559 Da
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form. In rabbit the ratios for Cys150:Cys154:Cys245 are 0.003:0.001:0.05
indicating that modification preference is Cys247>Cys150>Cys154. The Cys282
is not identified both by trypsin and chymotrypsin digestion as the peptide is
missing.
Amount of nitrosylation from mass spectrometry experiments was found to be low
which when compared to extent of nitrosylation determined by Saville’s method.
Factors affecting amount of nitrosylation during the process were examined. The
first factor which was considered was the choice of thiol blocker, MMTS and
NEM. MMTS and NEM were reacted with nitrosylated GAPDH. The excess
NEM or MMTS was removed by acetone precipitation. Nitrosylation was
measured by saville’s method before and after thiol blocker treatment. The result
indicates MMTS treatment precipitates GAPDH; however NEM treatment does
not precipitate protein and or loss of nitrosylation.
The next factor which was considering was biotin HPDP. Biotin-HPDP was
replaced with alkylating agent iodoacetamide. The results were described below.
Human GAPDH:
The only form the Cys152, Cys156, and Cys247 peptides identified in the
unmodified human GAPDH is the CNEM form, while both the C and CNEM
forms were identified in the +NO samples. If we assume that all of the
carbamidomethylated modified Cys residues are derived from Cys-NO and no
other forms of this residue are present, than we can utilize these targeted
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experiments to determine the %Cys-NO for each residue. For human GAPDH
these values are 93% for Cys152, 42% for Cys156 and 14% for Cys247.
Rabbit GAPDH:
The results from the rabbit GAPDH differ from human GAPDH in that both the
carbamidomethylated and CNEM forms were identified in the unmodified and
+NO samples, however, the amount of the carbamidomethylated forms in the
unmodified samples are small (less than 5%). At this time the source of these
residues is unclear, however, these residues may represent free thiol not blocked
with NEM. Despite this, the degree of modification at C150, C154, and C245 can
be determined from these experiments. For rabbit GAPDH the %C-NO values are
98% for Cys150, 96% for Cys154, and 75% for Cys245. All of these values are
higher than that observed for human GAPDH.

Fig. 3.24. The gel that was subjected to mass spectrometric analysis.
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Table.3.2.The extent of nitrosylation that has occurred at 3 cysteines in human GAPDH, the result
shows that c152 is the most susceptible with 93%, c156 with 42% nitrosylation and c247 with
14% nitrosylation.

Rabbit GAPDH + NO Rabbit GAPDH - NO

Table.3.3.The extent of nitrosylation that occurred at 3 cysteines in rabbit GAPDH as the fourth
cysteine was not detectable. The amount of nitrosylation found to be same on Cys150 and Cys154
and slightly more compared to Cys245.

From the above experiment we identified that all the cysteine residues present in
GAPDH

underwent

differential

nitrosylation,

in

the

preference

order

Cys152>Cys156>Cys247 in human GAPDH. In case of rabbit GAPDH Snitrosylation is in the order of Cys150~Cys154>Cys247.
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3.8 Making different GAPDH mutants and their effect on heme delivery after
S-nitrosylation:
In parallel we did different point mutations, by mutating cysteine in GAPDH to
further investigate whether s-nitrosylation of specific cysteine residues were
involved in heme transfer to apomyoglobin. Cysteine was replaced with serine.
There are 3 cysteines in human GAPDH at positions 152, 156 and 247. C152S
mutant was available in the lab. We made single point mutations at cysteines 156
and 247 sites. Double mutations include 152/247, where only cysteine 156 is
present, 156/247 where only cysteine 152 is present and 152/156 where only
cysteine 247 is present. We made a triple mutant where all the cysteines in
GAPDH were replaced by serine residues.
Once the mutations were done, yield of different transformation colonies was
checked. The results were shown below. The colonies with maximum protein
concentration were used for purification of different mutants of GAPDH.
Purification yields vary from 5 to 15 mg per 4 litre of culture of E.coli.
Western blot of mutants: The results of experiment of the different GAPDH were
given in Fig.3.25.
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c156s

C152/156/247s

C156/247s

GAPDH
+GST

1

2

3

1

2

3

1

C152/247S

C152/156S
GAPDH+
GST
1

2

3

1

2

3

Fig.3.25. In case of cysteine 156 mutant 3 colonies expressed equally, in case of cysteine 156 247
double mutant 2nd colony has more expression, in case of triple mutant 3 colonies express
equally. In case of cysteine 152/156 3rd colony has maximum expression; in case of cysteine
152/247 1st colony has maximum expression.

As described in our GAPDH purification protocol different mutants of GAPDH
were purified and the purity was examined by gel electrophoresis. The result
below shows that all the proteins were good in terms of purity (>85%).
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Wild type

C152/156S

C156/247S

C152/247S

C52/156/247S

C156S

C247S

Marker
250 kda
150 kda
100 kda
75 kda
50 kda
37 kda

GAPDH

25 kda

Fig.3.26. The gel represents different mutants of GAPDH, purity is ~85%.

The rate of heme transfer was examined from different mutants of GAPDH to
apomyoglobin. We considered nitrosylation as a factor to check which mutant has
a detectable difference on the rate of heme transfer after getting nitrosylated. By
this means we can investigate which nitrosylated cysteine has an effect on the rate
of heme transfer.
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Fig.3.27. In the above graph rate of heme transfer from non-nitrosylated GAPDH was represented
by red bar and black bar represents rate of heme transfer from nitrosylated GAPDH. The result
suggest that there was no affect of nitrosylation on rate of heme transfer other than 2 mutants
C152/156S and C156S

The above result suggests that there was no affect of S-nitrosylation on the rate of
heme transfer other than 2 mutants a.) C152/156S where both cysteines 152 and
156 were replaced with serines and only cysteine 247 is present. Upon
nitrosylation the rate of heme transfer doubled that of the corresponding nonnitrosylated protein but the difference is not substantial b.) C156S which has
cysteines 152 and 247 also shows double the rate of heme transfer but the
difference is not substantial.
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CHAPTER IV
CONCLUDING REMARKS AND FUTURE INVESTIGATIONS

Based on the results presented in this thesis, we conclude that S-nitrosylation of
cysteines in human GAPDH has no affect on rate of heme transfer to
apomyoglobin. The factors that affect the extent of nitrosylation included dose of
nitrosylation donor in case of human GAPDH and pH in the case of rabbit
GAPDH (alkaline pH increased the extent of nitrosylation). Nitrosylated GAPDH
was more stable at 4oC than at room temperature. The presence of reducing agents
or oxygen did not affect the yield of nitrosylation. The mass spectrometry results
suggest that the extent of nitrosylation on each individual cysteine is speciesspecific as the cysteines present in rabbit and human GAPDH’s displayed different
extents of nitrosylation. In case of human GAPDH the extent of nitrosylation is in
order of Cys152 (93%)>Cys156 (42%)>Cys247 (14%), whereas in rabbit GAPDH
the extent of nitrosylation is in order of Cys150 (98%) ~Cys156 (96%)>Cys247
(75%). From
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here, there are a few topics that can be further explored in order to fully
understand the mechanism of heme transfer from GAPDH.
a.) Even though we have not seen the effect of S-nitrosylation on rate of heme
transfer from GAPDH, there could be other properties of GAPDH which may
possibly be affected. We could explore the effect of S-nitrosylation on the binding
affinity (Kon) of heme to GAPDH. We could explore how the protein-protein
interactions of GAPDH with heme-protein differ, once the GAPDH is Snitrosylated.
b.) We could explore how the properties of heme are affecting the rate of heme
transfer after nitrosylation. This can be tested by using different heme analogues
like meso-heme, deutero-heme, Zn+2-heme and Co+2-heme. By investigating this,
we can examine whether the structural or chemical properties of heme have any
effect on rate of heme transfer after nitrosylation.
c.) We could test GAPDH from other organisms to see whether the specific
nitrosylation has any effect on the rate of heme transfer. This can be examined
using site directed mutagenesis on cysteine residues of rabbit and bacterial
GAPDH’s. One could investigate whether, other organism GAPDH’s behave in a
similar way after nitrosylation.
d.) We have to yet to identify which aminoacids are ligating the heme. Some of
our preliminary data suggest it may be histidine or cysteine. Recently, our lab has
observed preliminarily heme binding is not reduced after mutating cysteines,
therefore ruling out the cysteines as ligands. This can be done by mutating the
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histidines and see whether these mutations has any effect on heme binding
property of GAPDH. Histidine specific chemical modification can also be
considered as an alternative.
The results from this work and future investigations can help better understand the
mechanism of heme transfer from GAPDH to many physiologically relevant apoprotein targets such as apo-NOS, apo-cytochrome p450.
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